New insights into NPP1 function: Lessons from clinical and animal studies

Bone

Volumn 51, Issue 5, 2012, Pages 961-968

  Mackenzie, N C W ^a   Huesa, C ^a   Rutsch, F ^b   MacRae, V E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

ENPP1; FGF 23; GACI; Hypophosphataemia; Insulin; Vascular calcification

Indexed keywords

CALCIUM PHOSPHATE; INSULIN; NUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; BONE DISEASE; BONE MINERALIZATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 GENE; GENE; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENERALISED ARTERIAL CALCIFICATION IN INFANT; GLUCOSE HOMEOSTASIS; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OSSIFICATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSEUDOXANTHOMA ELASTICUM; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE CALCIFICATION;

ANIMALS; BONE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES;

EID: 84867049936     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.07.014     Document Type: Review

References (99)

1. Rutsch F., Ruf N., Vaingankar S., Toliat M.R., Suk A., Hohne W., et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003, 34:379-381.
2. Rutsch F., Vaingankar S., Johnson K., Goldfine I., Maddux B., Schauerte P., et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001, 158:543-554.
3. Levy-Litan V., Hershkovitz E., Avizov L., Leventhal N., Bercovich D., Chalifa-Caspi V., et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010, 86:273-278.
4. Lorenz-Depiereux B., Schnabel D., Tiosano D., Hausler G., Strom T.M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010, 86:267-272.
5. Ermakov S., Toliat M.R., Cohen Z., Malkin I., Altmueller J., Livshits G., et al. Association of ALPL and ENPP1 gene polymorphisms with bone strength related skeletal traits in a Chuvashian population. Bone 2010, 46:1244-1250.
6. Maddux B.A., Sbraccia P., Kumakura S., Sasson S., Youngren J., Fisher A., et al. Membrane glycoprotein PC-1 and insulin-resistance in non-insulin-dependent diabetes-mellitus. Nature 1995, 373:448-451.
7. Frittitta L., Youngren J., Vigneri R., Maddux B.A., Trischitta V., Goldfine I.D. PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia 1996, 39:1190-1195.
8. Meyre D., Bouatia-Naji N., Tounian A., Samson C., Lecoeur C., Vatin V., et al. Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet 2005, 37:863-867.
9. Sakamoto M., Hosoda Y., Kojimahara K., Yamazaki T., Yoshimura Y. Arthritis and ankylosis in TWY mice with hereditary multiple osteochondral lesions - with special reference to calcium deposition. Pathol Int 1994, 44:420-427.
10. Terakado A., Tagawa M., Goto S., Yamazaki M., Moriya H., Fujimura S. Elevation of alkaline-phosphatase activity induced by parathyroid-hormone in osteoblast like cells from the spinal hyperostotic mouse TWY (twy/twy). Calcif Tissue Int 1995, 56:135-139.
11. Baba H., Furusawa N., Fukuda M., Maezawa Y., Imura S., Kawahara N., et al. Potential role of streptozotocin in enhancing ossification of the posterior longitudinal ligament of the cervical spine in the hereditary spinal hyperostotic mouse (twy/twy). Eur J Histochem 1997, 41:191-202.
12. Furusawa N., Baba H., Imura S., Fukuda M. Characteristics and mechanism of the ossification of posterior longitudinal ligament in the tip-toe walking Yoshimura (twy) mouse. Eur J Histochem 1996, 40:199-210.
13. Okawa A., Nakamura I., Goto S., Moriya H., Nakamura Y., Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998, 19:271-273.
14. Okawa A., Goto S., Moriya H. Calcitonin simultaneously regulates both periosteal hyperostosis and trabecular osteopenia in the spinal hyperostotic mouse (twy/twy) in vivo. Calcif Tissue Int 1999, 64:239-247.
15. Sali A., Favaloro J., Terkeltaub R., Goding J. Germline deletion of the nucleoside triphosphate pyrophosphohydrolase (NTPPPH) plasma cell membrane glycoprotein-1 (PC-1) produces abnormal calcification of periarticular tissues. Ecto-ATPases and related ectoenzymes 1999, 267-282. Shaker Publishing. L. Vanduffel, R. Lemmems (Eds.).
16. Anderson H.C., Harmey D., Camacho N.P., Garimella R., Sipe J.B., Tague S., et al. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol 2005, 166:1711-1720.
17. Buckley M.F., Loveland K.A., McKinstry W.J., Garson O.M., Goding J.W. Plasma-cell membrane glycoprotein PC-1 - cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem 1990, 265:17506-17511.
18. Funakoshi I., Kato H., Horie K., Yano T., Hori Y., Kobayashi H., et al. Molecular-cloning of cDNAs for human fibroblast nucleotide pyrophosphatase. Arch Biochem Biophys 1992, 295:180-187.
19. Bollen M., Gijsbers R., Ceulemans H., Stalmans W., Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 2000, 35:393-432.
20. Nitschke Y., Weissen-Plenz G., Terkeltaub R., Rutsch F. Npp1 promotes atherosclerosis in ApoE knockout mice. J Cell Mol Med 2011, 15:2273-2283.
21. Terkeltaub R.A. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 2001, 281:C1-C11.
22. I) in pathologic calcification of articular cartilage. Front Biosci 2005, 10:988-997.
23. Goding J.W., Terkeltaub R., Maurice M., Deterre P., Sali A., Belli S.I. Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. Immunol Rev 1998, 161:11-26.
24. Stefan C., Jansen S., Bollen M. Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signal 2006, 2:361-370.
25. Clair T., Lee H.Y., Liotta L.A., Stracke M.L. Autotaxin is an exoenzyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. J Biol Chem 1997, 272:996-1001.
26. Uriarte M., Stalmans W., Hickman S., Bollen M. Phosphorylation and nucleotide-dependent dephosphorylation of hepatic polypeptides related to the plasma-cell differentiation antigen PC-1. Biochem J 1993, 293:93-100.
27. Landt M., Butler L.G. 5'-Nucleotide phosphodiesterase - isolation of covalently bound 5'-monophosphate, an intermediate in catalytic mechanism. Biochemistry 1978, 17:4130-4135.
28. Anderson H.C. Matrix vesicles and calcification. Curr Rheumatol Rep 2003, 5:222-226.
29. Johnson K.A., Hessle L., Vaingankar S., Wennberg C., Mauro S., Narisawa S., et al. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1365-R1377.
30. i and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003, 18:994-1004.
31. Hessle L., Johnson K.A., Anderson H.C., Narisawa S., Sali A., Goding J.W., et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 2002, 99:9445-9449.
32. Harmey D., Hessle L., Narisawa S., Johnson K.A., Terkeltaub R., Millan J.L. Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank - an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004, 164:1199-1209.
33. Harmey D., Johnson K.A., Zelken J., Camacho N.P., Hoylaerts M.F., Noda M., et al. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res 2006, 21:1377-1386.
34. Sugita A., Kawai S., Hayashibara T., Amano A., Ooshima T., Michigami T., et al. Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis. J Biol Chem 2011, 286:3094-3103.
35. Yadav M.C., Simao A.M.S., Narisawa S., Huesa C., McKee M.D., Farquharson C., et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 2011, 26:286-297.
36. Terkeltaub R., Rosenbach M., Fong F., Goding J. Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma-cell membrane glycoprotein-1 - relevance to calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum 1994, 37:934-941.
37. Ho A.M., Johnson M.D., Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-270.
38. Hakim F.T., Cranley R., Brown K.S., Eanes E.D., Harne L., Oppenheim J.J. Hereditary joint disorder in progressive ankylosis (ank/ank) mice. I. Association of calcium hydroxyapatite deposition with inflammatory arthropathy. Arthritis Rheum 1984, 27:1411-1420.
39. Addison W.N., Azari F., Sorensen E.S., Kaartinen M.T., McKee M.D. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 2007, 282:15872-15883.
40. -/- mice. PLoS One 2012, 7:e32177.
41. Nam H.K., Liu J., Li Y., Kragor A., Hatch N.E. Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation. J Biol Chem 2011, 286:39059-39071.
42. Nitschke Y., Baujat G., Botschen U., Wittkampf T., du Moulin M., Stella J., et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet 2012, 90:25-39.
43. Rutsch F., Nitschke Y., Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 2011, 109:578-592.
44. Moran J.J. Idiopathic arterial calcification of infancy: a clinicopathologic study. Pathol Annu 1975, 10:393-417.
45. Rutsch F., Schauerte P., Kalhoff H., Petrarulo M., August C., Diekmann L. Low levels of urinary inorganic pyrophosphate indicating systemic pyrophosphate deficiency in a boy with idiopathic infantile arterial calcification. Acta Paediatr 2000, 89:1265-1269.
46. Rutsch F., Boeyer P., Nitschke Y., Ruf N., Lorenz-Depierieux B., Wittkampf T., et al. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 2008, 1:133-140.
47. Ramjan K.A., Roscioli T., Rutsch F., Sillence D., Munns C.F.J. Generalized arterial calcification of infancy: treatment with bisphosphonates. Nat Clin Pract Endocrinol Metab 2009, 5:167-172.
48. Sholler G.F., Yu J.S., Bale P.M., Hawker R.E., Celermajer J.M., Kozlowski K. Generalized arterial calcification of infancy - 3 case reports, including spontaneous regression with long-term survival. J Pediatr 1984, 105:257-260.
49. Ciana G., Trappan A., Bembi B., Benettoni A., Maso G., Zennaro F., et al. Generalized arterial calcification of infancy: two siblings with prolonged survival. Eur J Pediatr 2006, 165:258-263.
50. Li Q., Schumacher W., Jablonski D., Siegel D., Uitto J. Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene. Br J Dermatol 2012, 166:1107-1111.
51. Le Saux O., Urban Z., Tschuch C., Csiszar K., Bacchelli B., Quaglino D., et al. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 2000, 25:223-227.
52. Ringpfeil F., Lebwohl M.G., Christiano A.M., Uitto J. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A 2000, 97:6001-6006.
53. -/- mice. Arterioscler Thromb Vasc Biol 2005, 25:686-691.
54. Nakamura I., Ikegawa S., Okawa A., Okuda S., Koshizuka Y., Kawaguchi H., et al. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet 1999, 104:492-497.
55. Koshizuka Y., Kawaguchi H., Ogata N., Ikeda T., Mabuchi A., Seichi A., et al. Nucleotide pyrophosphatase gene polymorphism associated with ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res 2002, 17:138-144.
56. Tahara M., Aiba A., Yamazaki M., Ikeda Y., Goto S., Moriya H., et al. The extent of ossification of posterior longitudinal ligament of the spine associated with nucleotide pyrophosphatase gene and leptin receptor gene polymorphisms. Spine 2005, 30:877-880.
57. Zhu D., Mackenzie N.C.W., Millan J.L., Farquharson C., MacRae V.E. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011, 6:e19595.
58. -/- mice. J Vasc Res 2011, 48:227-235.
59. Bowman M.H., Wilk J., Heydemann A., Kim G., Rehman J., Lodato J.A., et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 2010, 106:145-U291.
60. Basta G., Corciu A.I., Vianello A., Del Turco S., Foffa I., Navarra T., et al. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis 2010, 210:614-618.
61. Hunter G.K., Kyle C.L., Goldberg H.A. Modulation of crystal-formation by bone phosphoproteins - structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994, 300:723-728.
62. Boskey A.L., Maresca M., Ullrich W., Doty S.B., Butler W.T., Prince C.W. Osteopontin-hydroxyapatite interactions in-vitro - inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner 1993, 22:147-159.
63. Speer M.Y., McKee M.D., Guldberg R.E., Liaw L., Yang H.Y., Tung E., et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002, 196:1047-1055.
64. Steitz S.A., Speer M.Y., McKee M.D., Liaw L., Almeida M., Yang H., et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002, 161:2035-2046.
65. Matsui Y., Rittling S.R., Okamoto H., Inobe M., Jia N., Shimizu T., et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:1029-1034.
66. Bruemmer D., Collins A.R., Noh G., Wang W., Territo M., Arias-Magallona S., et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003, 112:1318-1331.
67. Cote N., El Husseini D., Pepin A., Bosse Y., Bouvet C., Audet A., et al. ATP release acts as survival signal and prevents the mineralization of aortic valve by P2Y(2) and PI3K/AKT signaling. Circulation 2011, 124:A11911.
68. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008, 118:3820-3828.
69. Liu S., Zhou J., Tang W., Menard R., Feng J.Q., Quarles L.D. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 2008, 295:E254-E261.
70. Liu S.G., Zhou J.P., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006, 291:E38-E49.
71. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
72. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006, 281:6120-6123.
73. Martin A., Liu S., David V., Li H., Karydis A., Feng J.Q., et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011, 25:2551-2562.
74. Sitara D., Kim S., Razzaque M.S., Bergwitz C., Taguchi T., Schuler C., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4:10.
75. Srivaths P.R., Goldstein S.L., Silverstein D.M., Krishnamurthy R., Brewer E.D. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011, 26:945-951.
76. Nasrallah M.M., El-Shehaby A.R., Salem M.M., Osman N.A., El Sheikh E., El Din U.A.A.S. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010, 25:2679-2685.
77. Mirza M.A.I., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
78. Mirza M.A.I., Hansen T., Johansson L., Ahlstrom H., Larsson A., Lind L., et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009, 24:3125-3131.
79. Mirza M.A.I., Larsson A., Melhus H., Lind L., Larsson T.E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009, 207:546-551.
80. Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
81. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004, 23:421-432.
82. Stubbs J.R., Liu S., Tang W., Zhou J., Wang Y., Yao X., et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007, 18:2116-2124.
83. Bai X.Y., Miao D.S., Li J.R., Goltzman D., Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004, 145:5269-5279.
84. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004, 314:409-414.
85. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha 1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004, 145:3087-3094.
86. Lim K.L.T., Molostvov G., Lee C., Lam F., Zehnder D., Hsiao L.L. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to FGF-23. Circulation 2012, 125(18):2243-2255.
87. Frittitta L., Spampinato D., Solini A., Nosadini R., Goldfine I.D., Vigneri R., et al. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects - evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 1998, 47:1095-1100.
88. Maddux B.A., Goldfine I.D. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 2000, 49:13-19.
89. Youngren J.F., Maddux B.A., Sasson S., Sbraccia P., Tapscott E.B., Swanson M.S., et al. Skeletal muscle content of membrane glycoprotein PC-1 in obesity - relationship to muscle glucose transport. Diabetes 1996, 45:1324-1328.
90. Maddux B.A., Chang Y.N., Accili D., McGuinness O.P., Youngren J.F., Goldfine I.D. Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab 2006, 290:E746-E749.
91. Pan W., Ciociola E., Saraf M., Tumurbaatar B., Tuvdendorj D., Prasad S., et al. Metabolic consequences of ENPP1 overexpression in adipose tissue. Am J Physiol Endocrinol Metab 2011, 301:E901-E911.
92. Zhou H.H., Chin C.-N., Wu M., Ni W., Quan S., Liu F., et al. Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo. Eur J Pharmacol 2009, 616:346-352.
93. Di Paola R., Caporarello N., Marucci A., Dimatteo C., Iadicicco C., Del Guerra S., et al. ENPP1 affects insulin action and secretion: evidences from in vitro studies. PLoS One 2011, 6:e19462.
94. Goldfine I.D., Maddux B.A., Youngren J.F., Frittitta L., Trischitta V., Dohm G.L. Membrane glycoprotein PC-1 and insulin resistance. Mol Cell Biochem 1998, 182:177-184.
95. Tanyolaç S., Bremer A.A., Hodoglugil U., Movsesyan I., Pullinger C.R., Heiner S.W., Malloy M.J., Kane J.P., Goldfine I.D. Genetic variants of the ENPP1/PC-1 gene are associated with hypertriglyceridemia in male subjects. 2009;7: 543-548.
96. Pizzuti A., Frittitta L., Argiolas A., Baratta R., Goldfine I.D., Bozzali M., et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999, 48:1881-1884.
97. Goldfine I.D., Maddux B.A., Youngren J.F., Reaven G., Accili D., Trischitta V., et al. The role of membrane glycoprotein plasma cell antigen 1 ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev 2008, 29:62-75.
98. Willer C.J., Bonnycastle L.L., Conneely K.N., Duren W.L., Jackson A.U., Scott L.J., et al. Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes 2007, 56:256-264.
99. McAteer J.B., Prudente S., Bacci S., Lyon H.N., Hirschhorn J.N., Trischitta V., et al. The EBPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 2008, 57:1125-1130.